These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31099804)

  • 1. Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients.
    Wood LS; Moldawer NP; Lewis C
    Clin J Oncol Nurs; 2019 Jun; 23(3):271-280. PubMed ID: 31099804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
    Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
    J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
    Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
    Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.
    Naidoo J; Zhang J; Lipson EJ; Forde PM; Suresh K; Moseley KF; Mehta S; Kwatra SG; Parian AM; Kim AK; Probasco JC; Rouf R; Thorne JE; Shanbhag S; Riemer J; Shah AA; Pardoll DM; Bingham CO; Brahmer JR; Cappelli LC
    J Natl Compr Canc Netw; 2019 Jun; 17(6):712-720. PubMed ID: 31200355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of immune-related adverse events resulting from immune checkpoint blockade.
    Baroudjian B; Arangalage D; Cuzzubbo S; Hervier B; Lebbé C; Lorillon G; Tazi A; Zalcman G; Bouattour M; Lioté F; Gautier JF; Brosseau S; Lourenco N; Delyon J;
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):209-222. PubMed ID: 30572735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
    Khan OF; Monzon J
    Curr Oncol; 2020 Apr; 27(Suppl 2):S43-S50. PubMed ID: 32368173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).
    Majem M; García-Martínez E; Martinez M; Muñoz-Couselo E; Rodriguez-Abreu D; Alvarez R; Arance A; Berrocal A; de la Cruz-Merino L; Lopez-Martin JA
    Clin Transl Oncol; 2020 Feb; 22(2):213-222. PubMed ID: 31993963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacist's role in immune-related adverse events management: real-world incidence and risk evaluation from immunotherapy.
    Meanwatthana J; Chantarasap P; Chuatrisorn I; Wiriya T; Jitawatanarat P
    Int J Pharm Pract; 2022 Aug; 30(4):377-382. PubMed ID: 35731644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.
    Psimaras D; Velasco R; Birzu C; Tamburin S; Lustberg M; Bruna J; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S74-S85. PubMed ID: 31393660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of immune related adverse events induced by immune checkpoint inhibition.
    Teufel A; Zhan T; Härtel N; Bornschein J; Ebert MP; Schulte N
    Cancer Lett; 2019 Aug; 456():80-87. PubMed ID: 31051213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe neurologic complications of immune checkpoint inhibitors: a single-center review.
    Mancone S; Lycan T; Ahmed T; Topaloglu U; Dothard A; Petty WJ; Strowd RE
    J Neurol; 2018 Jul; 265(7):1636-1642. PubMed ID: 29761297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
    Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
    Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy Toxicities.
    Sanchez K; Page DB; Urba W
    Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune complications of immunotherapy: pathophysiology and management.
    Chan KK; Bass AR
    BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects of immunotherapy: a constant challenge for oncologists.
    Scotté F; Ratta R; Beuzeboc P
    Curr Opin Oncol; 2019 Jul; 31(4):280-285. PubMed ID: 30925538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.
    de Malet A; Antoni G; Collins M; Soularue E; Marthey L; Vaysse T; Coutzac C; Chaput N; Mateus C; Robert C; Carbonnel F
    Eur J Cancer; 2019 Jan; 106():106-114. PubMed ID: 30476730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related adverse events of immune checkpoint inhibitors: a brief review.
    Myers G
    Curr Oncol; 2018 Oct; 25(5):342-347. PubMed ID: 30464684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.